Related Experiment Videos
Evolving knowledge and therapy of inflammatory bowel disease
Joshua R Korzenik1, Daniel K Podolsky
1Gastrointestinal Unit, Department of Medicine, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA.
Nature Reviews. Drug Discovery
|March 7, 2006
Summary
Novel therapies for inflammatory bowel disease (IBD) target T-cell cytokines and adhesion molecules. Strategies also explore stimulating innate immunity and manipulating gut bacteria with probiotics and prebiotics.
Area of Science:
- Gastroenterology
- Immunology
- Microbiology
Background:
- Inflammatory bowel disease (IBD) research is advancing rapidly due to improved understanding of its pathophysiology.
- Novel therapeutic agents are crucial for managing IBD effectively.
Purpose of the Study:
- To review emerging therapeutic strategies for inflammatory bowel disease.
- To highlight new targets including cytokines, adhesion molecules, and the gut microbiome.
Main Methods:
- Review of recent advances in IBD pathophysiology and therapeutic development.
- Discussion of biologic agents targeting cytokines (IL-12, interferon-gamma) and adhesion molecules.
- Exploration of novel approaches like recombinant human granulocyte-macrophage colony-stimulating factor and microbiome manipulation.
Main Results:
- Biologics targeting IL-12 and interferon-gamma show potential.
- Selective adhesion molecule blockade yields mixed but promising results.
- Recombinant human granulocyte-macrophage colony-stimulating factor may benefit active Crohn's disease by boosting innate immunity.
- Probiotics and prebiotics are being investigated for their role in manipulating gut bacteria.
Conclusions:
- Multiple novel therapeutic avenues are under active investigation for IBD.
- Targeting immune pathways and the gut microbiome represents a promising future for IBD treatment.